Does Timing of Androgen Deprivation Influence Radiation-Induced Toxicity? A Secondary Analysis of Radiation Therapy Oncology Group Protocol 9413

Urology

Volumn 72, Issue 5, 2008, Pages 1125-1129

  Taussky, Daniel ^a   Bae, Kyounghwa ^b   Bahary, Jean Paul ^a   Roach III, Mack ^c   Lawton, Colleen A ^d   Shipley, William U ^e   Sandler, Howard M ^f  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; FLUTAMIDE; TESTOSTERONE;

ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; GASTROINTESTINAL TOXICITY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION FIELD; RADIATION INJURY; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CHEMOTHERAPY, ADJUVANT; CLINICAL PROTOCOLS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY; RETROSPECTIVE STUDIES; RISK FACTORS; TESTOSTERONE;

EID: 54449083092     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.11.067     Document Type: Article

References (21)

1. Roach III M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911
2. Zelefsky M.J., Moughan J., Owen J., et al. Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer. Int J Radiat Oncol Biol Phys 59 (2004) 1053-1061
3. Sanguineti G., Agostinelli S., Foppiano F., et al. Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma. Br J Cancer 86 (2002) 1843-1847
4. Liu M., Pickles T., Agranovich A., et al. Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy. Int J Radiat Oncol Biol Phys 58 (2004) 59-67
5. Wachter S., Gerstner N., Goldner G., et al. Rectal sequelae after conformal radiotherapy of prostate cancer: dose-volume histograms as predictive factors. Radiother Oncol 59 (2004) 65-70
6. Fiorino C., Cozzarini C., Vavassori V., et al. Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. Radiother Oncol 64 (2002) 1-12
7. Feigenberg S.J., Hanlon A.L., Horwitz E.M., et al. Long-term androgen deprivation increases grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 62 (2005) 397-405
8. Palma D., Pickles T., and Tyldesley S. Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer. BJU Int 100 (2007) 315-319
9. Teloken C., Da Ros C.T., Caraver F., et al. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol 174 (2005) 2178-2180
10. D'Amico A.V., Denham J.W., Crook J., et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25 (2007) 2420-2425
11. Zelefsky M.J., and Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology 49 3A suppl (1997) 38-45
12. Hanks G.E., Pajak T.F., Porter A., et al. Radiation Therapy Oncology Group: phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
13. Lawton C.A., Winter K., Grignon D., et al. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol 23 (2005) 800-807
14. Valicenti R.K., Winter K., Cox J.D., et al. RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?. Int J Radiat Oncol Biol Phys 57 (2003) 614-620
15. Williams M.B., Hernandez J., and Thompson I. Luteinizing hormone-releasing hormone agonist effects on skeletal muscle: how hormonal therapy in prostate cancer affects muscular strength. J Urol 173 (2005) 1067-1071
16. Nejat R.J., Rashid H.H., Bagiella E., et al. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 164 (2000) 1891-1894
17. Padula G.D., Zelefsky M.J., Venkatraman E.S., et al. Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 52 (2002) 439-443
18. Wang C., Catlin D.H., Demers L.M., et al. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 89 (2004) 534-543
19. Matsumoto A.M., and Bremner W.J. Serum testosterone assays-accuracy matters. J Clin Endocrinol Metab 89 (2004) 520-524
20. Denis L.J., and Griffiths K. Endocrine treatment in prostate cancer. Semin Surg Oncol 18 (2000) 52-74
21. Fine J.P., and Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94 (1999) 496-509